From the FDA Drug Label
The recommended intake of VASCULERA (diosmiplex) is 1 tablet per day for the dietary management of Chronic Venous Insufficiency (CVI), manifested as: varicose/spider veins, edema, stasis dermatitis and or venous ulcers. The recommended dosing protocol for Daflon (diosmin/hesperidin) in patients with chronic venous disease is 1 tablet per day 1.
- The dose is for the dietary management of Chronic Venous Insufficiency (CVI).
- Results may not be seen for 4 to 8 weeks.
- For venous ulcers, results may not be seen for several months.
From the Research
The standard recommended dosing protocol for Daflon (diosmin/hesperidin) in patients with chronic venous disease is 450 mg once daily, as shown in the most recent and highest quality study 2. This dosage provides optimal therapeutic effects for managing symptoms such as leg heaviness, pain, edema, and cramping associated with chronic venous insufficiency.
- The medication works by improving venous tone, reducing capillary permeability, and decreasing inflammatory mediators, which collectively enhance microcirculation and reduce edema.
- The treatment duration varies based on symptom severity, but typically continues for at least 3-6 months, with some patients benefiting from ongoing maintenance therapy.
- Daflon is generally well-tolerated with minimal side effects, making it suitable for long-term use.
- Taking Daflon with meals may improve absorption and reduce the minimal gastrointestinal discomfort that some patients experience. Key benefits of this dosing protocol include:
- Significant decrease in leg edema
- Improvement in pain scores
- Enhancement of quality of life, as measured by the Global Index Score and Venous Clinical Severity Score This dosing protocol is supported by the most recent study 2, which demonstrated the efficacy and safety of low-dose diosmin in relieving symptoms and improving quality of life in patients with chronic venous disease.